Deciphera's Metabolic Disease Programs

Deciphera's metabolic disease programs are currently targeting p38-alpha, MK2 and AXL kinases. Switch control inhibitors have been discovered and optimized to provide development candidates to treat arthritis and other human inflammatory diseases.

p38-alpha Program

Deciphera's p38-alpha kinase program has identified a highly potent and orally bioavailable compound series with unprecedented selectivity against a broad range of other kinase targets. We believe that our selectivity profile will translate to greater safety and reduced side effects relative to the ATP-site directed inhibitor approaches which have thus far proven too toxic for clinical use in the treatment of chronic inflammatory diseases.

MK2 Program

MK2 is an important kinase in the proinflammatory p38 MAPK signaling pathway, which is designed to sense inflammatory and other stress signals (e.g., hyperosmolarity and oxidative stress). Deciphera has identified a class of switch inhibitors directed towards MK2 which show selectivity away from p38-alpha kinase. This program is in lead discovery phase.

AXL Program

Recent studies have established the GAS6-AXL-PI3K-AKT pathway as an anti-apoptotic mechanism for vascular smooth muscle cells that may be important in the response to vascular injury. These studies implicate AXL as a potential mediator of vascular smooth muscle migration and proliferation caused by vascular injury and G protein-coupled receptor agonists. Deciphera has identified low nanomolar inhibitors of AXL that provide excellent starting points for lead optimization efforts.

Deciphera Pharmaceuticals, LLC
4950 Research Park Way
Lawrence, KS 66047

785-838-3767 phone
785-838-3747 fax
info@deciphera.com

Copyright © Deciphera Pharmaceuticals, LLC 2002-2009
All Rights Reserved